Fast Locator 2011-2012: Cambridge Major Laboratories, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Cambridge Major Laboratories, Inc.



Cambridge Major Laboratories (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. CML produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API), from early preclinical development to commercial manufacture. Operating from FDA-inspected facilities in the U.S. and Europe, CML is organized along five key integrated Centers of Excellence:

5 Centers of Excellence:

Process Chemistry

We understand that maintaining a high ratio of Ph.D. scientists is essential to provide rapid and reliable chemistry services to support early preclinical quantities through full production at plant scale. Because our Ph.D. scientists follow the projects from the lab into the plant, we have the expertise to troubleshoot any possible issues that may arise during the scale up phase. Whether you need a synthetic route completely developed, or can provide us a fully developed process, we’ll get the job done safely, efficiently, and on specification.

API Manufacturing

CML’s state of the art manufacturing facilities meet global regulatory requirements, GMP compliance standards, and are FDA inspected and approved. By leveraging the range of equipment in our manufacturing facilities, our pharmaceutical contract manufacturing services can support the drug discovery process through API synthesis for all stages of clinical trials. We conduct GMP manufacturing of APIs from grams to multi-ton quantities.

Solid State Chemistry

CML combines its leading position in process chemistry with solid state chemistry to provide clients the most optimal solutions ranging from polymorph screens to optimizing crystallization conditions along a synthetic pathway. In a world where development timelines are continually squeezed, there is an opportunity to optimize the drug substance development path by having the solid state chemist work in close collaboration with the process chemist at every step of the synthesis pathway.

Analytical Services

CML provides a wide variety of analytical support services for development and manufacturing, consistent with the appropriate phase of drug development. Our method development philosophy is “fit for purpose,” meaning we will provide the appropriate level of development/validation to support your API based on where your compound is in the development cycle.

Quality Assurance

The Quality Assurance (QA) team at CML ensures that every stage of the development and manufacturing process meets customer and regulatory expectations. Whether the product is going into the domestic or international market, CML will ensure that all compliance and quality standards are met.

Regions where services are provided:

Cambridge Major serves clients across the United States, Europe, Asia and around the world.


Contact:

W130 N10497 Washington Drive
Germantown, WI 53022
tel. 262.251.5044
info@c-mlabs.com

www.c-mlabs.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here